Manufacture of ampicillin sodium sterile powder for parenteral reconstitution is executed as an aseptic crystallization and filling operation rather than terminal sterilization, because the beta-lactam ring is degraded by moist heat. The API solution in Water for Injection is cooled to 8–12 °C before passage through a 0.22 µm PVDF sterilizing filter; antisolvent crystallization is then carried out under Grade A unidirectional airflow with a solvent system controlled to ICH Q3C Class 3 residual solvent limits. The wet crystal mass is dried in an agitated vacuum dryer at 28–35 °C and ≤5.0 mbar until loss on drying is ≤2.0% w/w, then passed through a low-shear conical mill at 800–1,200 rpm to control bulk density and reconstitution time. In-line laser particle sizing is used to maintain a median particle size of 40–80 µm; batches exceeding this window exhibit altered filling weight consistency and longer reconstitution times. On multi-head rotary piston fillers running at 180–240 vials per minute, powder bridging in the hopper has been observed when bulk density drops below 0.30 g/mL. The failure mode is corrected by installation of a mechanical bridge-breaker and by controlling vacuum drying endpoint between 1.0% and 2.0% w/w residual moisture. Over-drying below 1.0% w/w increases electrostatic charge and dusting, while under-drying above 2.0% w/w impairs flowability and raises water activity beyond 0.30.

Compendial release tests for the sterile powder include USP Chapter 71, USP Chapter 85, USP Chapter 788, USP Chapter 790, and USP Chapter 921. The vial fill mass is calculated from the measured assay value to deliver 250 mg, 500 mg, 1 g, or 2 g ampicillin per vial; the single-entity product contains no excipients, so no formulation addition ratio is applied beyond the API itself. Endotoxin limits are derived from the maximum adult daily dose in USP Chapter 85; container closure integrity is verified under USP Chapter 1207 and safety of primary packaging under 21 CFR 211.94. The final container type is Type I borosilicate glass vial with bromobutyl rubber stopper and aluminium flip-off seal. Aseptic filling is performed inside an isolator with vaporized hydrogen peroxide biodecontamination; the Grade A zone is maintained at ISO 5 per ISO 14644-1. Fill weight is monitored by in-line checkweighing at ±1.0% tolerance; stoppers are pre-dried to ≤0.5% w/w moisture and held at ≤30% RH before insertion. Capping torque is maintained at 0.8–1.2 N·m, and the sealed vials undergo visual inspection, leak testing, and oxygen headspace analysis with residual oxygen ≤0.5%. Operational boundaries include a holding time of ≤8 hours between sterile filtration and filling, because ampicillin sodium hydrolysis in aqueous solution at pH 8.0–10.0 accelerates above 25 °C. Documented incompatibilities include dextrose-containing intravenous diluents and aminoglycoside antibiotics; reconstitution in normal saline is preferred for clinical use. Terminal product type is sterile powder for injection for intravenous or intramuscular use after reconstitution.

What Suspending-Agent Ratios Prevent Caking in Ampicillin Sodium Dry Syrup?

For paediatric oral suspensions, ampicillin sodium dry powder is filled into amber glass bottles or laminated sachets and reconstituted to deliver 125 mg or 250 mg ampicillin per 5 mL. The dry blend is composed of 25–45% w/w API, 40–55% w/w sucrose or spray-dried mannitol, 2–5% w/w sodium carboxymethylcellulose or xanthan gum, 0.2–0.8% w/w sodium benzoate, and 0.5–1.5% w/w colloidal silicon dioxide. The addition ratio must be validated for sedimentation volume, redispersibility, and deliverable volume, because ampicillin sodium's high aqueous solubility alters suspension rheology and can lead to dose inaccuracy if the suspending agent is insufficient.

Downstream processing uses a low-shear tumble blender operated at 12–18 rpm for 20–30 minutes, followed by dry sieving through a 0.5 mm stainless-steel screen; aqueous granulation is avoided because ampicillin sodium is freely soluble and forms a paste that hydrolyzes under heated drying. High-shear mixing is not employed because frictional heat generation above 30 °C triggers softening of the sodium salt. The powder is filled into bottles at 20–25 °C and ≤30% RH using an auger filler with ±5% fill weight tolerance. Residual water content is maintained at ≤2.0% w/w per USP Chapter 921, and desiccant sachets are inserted when the bottle headspace humidity exceeds 30% RH after capping. Batch-to-batch variance in the API bulk density after sieving has been observed to shift fill weight by up to ±4% if the blender speed and filling time are not controlled.

Compliance includes USP Chapter 698 for deliverable volume, USP Chapter 905 for content uniformity, ICH Q1A for stability in climate zone IVa, and 21 CFR 211.100 for written production procedures. Terminal product types are powder for oral suspension in 60 mL, 100 mL, and 120 mL bottles. A documented limiting operational condition is that the reconstituted oral suspension must be stored at 2–8 °C and discarded after 7 days if not consumed, due to hydrolytic loss of potency in aqueous media.

Because ampicillin sodium is freely soluble and hygroscopic, aqueous wet granulation is replaced by roller compaction or slugging in oral tablet manufacture. The API is pre-blended with 10–20% w/w microcrystalline cellulose, 5–10% w/w crospovidone, 0.5–1.5% w/w colloidal silicon dioxide, and 0.5–1.0% w/w magnesium stearate in a bin blender at 10–15 rpm for 15 minutes, then compacted at 2–5 kN/cm roll force. The compacted ribbons are milled through a 1.0 mm screen, lubricated, and compressed on a rotary tablet press with 8–15 kN main compression force and 3–6 kN precompression force. On high-speed rotary tablet presses at 60–80 rpm turret speed, powder sticking to lower punch faces is observed when the relative humidity exceeds 35% RH; the condition requires press stoppage, punch polishing, or addition of 0.5% w/w magnesium stearate to the pre-lubricated blend. If incoming ambient RH is above 60%, desiccant pre-conditioning of excipients is required before opening the blend container.

Tablet hardness is maintained at 6–9 kp and friability at ≤0.8% per USP Chapter 1216; disintegration time is tested by USP Chapter 701 and drug release by USP Chapter 711. The formulation is adjusted to deliver 250 mg or 500 mg ampicillin per tablet; ampicillin sodium addition ratio is determined by assay on the anhydrous basis and corrected for water content per USP Chapter 921. Environmental conditions in the compression suite are held at 20–25 °C and ≤25% RH, and product is transferred in sealed drums with desiccant because prolonged exposure to ambient moisture causes tablet capping and potency loss. Compliance includes 21 CFR 211.110 for in-process controls, 21 CFR 211.165 for release testing, and ICH Q3D for elemental impurities. The terminal product type is an immediate-release oral tablet with a moisture-barrier film coating. The coating dispersion, often based on hydroxypropyl methylcellulose with 2–3% w/w solids, is applied in a side-vented coating pan at 35–45 °C inlet air and ≤50% RH, with 2–3% weight gain. A specific limitation is that ampicillin sodium tablets are not appropriate for sustained-release matrices because the API dissolves rapidly at pH 1.2 and 6.8 in compendial dissolution media, which complicates extended gastric retention and controlled-release design.

Capsule Filling Parameters for Hygroscopic Ampicillin Sodium Blends

Automatic capsule filling with ampicillin sodium powder requires a separate low-humidity filling suite because the sodium salt adsorbs moisture rapidly and becomes sticky on contact with gelatin or HPMC shells. The powder blend is prepared to deliver 250 mg or 500 mg ampicillin per capsule; API content in the blend is usually 35–50% w/w, with 20–35% w/w pregelatinized starch or microcrystalline cellulose, 1–2% w/w sodium starch glycolate, and 0.25–0.75% w/w magnesium stearate. The addition ratio is validated for disintegration time and dissolution release; published data for this specific sodium-salt capsule configuration is limited compared with ampicillin trihydrate capsule systems.

Capsule filling is performed on a dosator-type machine at 15,000–60,000 capsules/hour with the hopper and bowl zone maintained at 20–25 °C and ≤20% RH. On a dosator capsule line, powder adhesion to dosator pins and shell crushing occurs when residual moisture exceeds 2.5% w/w; if the filling room dew point rises above 5 °C, the line must be stopped and desiccant rotors reactivated. In-process controls include mass variation at ±5%, shell moisture at 10–14% w/w for gelatin, and metal detection at ≤1.0 mm ferrous or ≤1.5 mm non-ferrous sensitivity. The filled capsules are band-sealed to reduce moisture ingress and then packed in HDPE bottles with 1 g molecular sieve desiccant.

Compliance standards include USP Chapter 905 for content uniformity, USP Chapter 711 for dissolution, USP Chapter 698 for capsule weight variation, and 21 CFR 211.122 for material inspection. Terminal product types are size 0 or size 00 immediate-release hard capsules. The limiting operational boundary is that exposing the powder blend to relative humidity above 35% RH for more than 30 minutes raises water activity above 0.30 and increases hydrolytic degradation, producing penicilloic acid-related impurities that fail the compendial impurity test.

The following table compiles the release and in-process thresholds routinely applied across the six downstream dosage forms.

For fixed-dose parenteral combinations, ampicillin sodium is co-blended with sulbactam sodium at a 2:1 ampicillin-to-sulbactam ratio, typically 1 g/0.5 g, 2 g/1 g, or 3 g/1.5 g per vial. The two sterile powders are dry blended in a vacuum-conveying aseptic blender at 10–20 rpm for 15–25 minutes, then filled as a single powder mixture. Blend uniformity is monitored by near-infrared spectroscopy with ≤5% RSD acceptance; segregation risk is controlled by matching particle-size distributions and by limiting blend holding time to ≤4 hours before filling.

Compliance includes USP Chapter 71, USP Chapter 85, USP Chapter 788, ICH Q3D, and EU GMP Annex 1; the fixed-dose combination is not terminally sterilized and requires a media fill validation with ≥4,000 filled units per line configuration. The downstream process includes sterile filling into 10 mL or 20 mL vials, capping, and reconstitution with Sterile Water for Injection to 20 mL or 40 mL. Terminal product type is injectable combination powder for intravenous or intramuscular use.

An operational limitation is the documented incompatibility between ampicillin sodium and aminoglycoside antibiotics in the same intravenous container; admixture with gentamicin or amikacin leads to inactivation of both compounds. In addition, prolonged residence in dextrose 5% or sodium bicarbonate solutions reduces ampicillin sodium potency by more than 10% within 2 hours at 25 °C. Published data for this specific configuration is limited for room-temperature extended infusions; therefore, reconstituted solutions are administered within 1 hour after dilution in normal saline.

When Ampicillin Sodium Is Used for Extemporaneous Oral Liquid Compounding

Hospital pharmacy compounding of ampicillin sodium into oral liquid dosage forms is carried out from sterile powder vials when no licensed oral suspension is available. The powder is reconstituted to a concentration of 25 mg/mL or 50 mg/mL using a suspending vehicle that may contain 0.1–0.3% w/w xanthan gum or 0.5–1.0% w/w carboxymethylcellulose sodium, buffered to pH 5.0–6.5. The formulation addition ratio depends on the labelled vial content and the final volume; compounding is performed according to USP Chapter 795 for non-sterile compounding and USP Chapter 797 when sterile preparation is required.

Downstream process uses a Class A laminar air flow cabinet or a USP 797 primary engineering control; the vial contents are transferred to a graduated amber glass bottle, the suspending vehicle is added in two aliquots to reduce foaming, and the mixture is shaken until uniform. Batch size is typically limited to 100–200 mL per patient, and beyond-use dating is assigned as 14 days under refrigeration at 2–8 °C. Terminal product types are patient-specific oral liquid preparations for paediatric or enteral administration, labelled with shake-well instructions.

Standards include 21 CFR 211.65 for equipment construction, CDC hygiene procedures, and FDA guidance on extemporaneous compounding of beta-lactam antibiotics. A documented operational boundary is that ampicillin sodium in aqueous oral vehicle at room temperature loses 10% potency after 24–48 hours; therefore, the preparation must be refrigerated and discarded beyond the assigned beyond-use date. Published data for ampicillin sodium oral liquid stability is limited beyond 14 days, so extended storage is outside validated use.